MedTech Acquisition (MedTech Acquisition) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 09, 2024)

View and export this data going back to 2020. Start your Free Trial

What is MedTech Acquisition 5-Year Yield-on-Cost %?

MedTech Acquisition's yield on cost for the quarter that ended in Jun. 2023 was 0.00.

The historical rank and industry rank for MedTech Acquisition's 5-Year Yield-on-Cost % or its related term are showing as below:

MTACU's 5-Year Yield-on-Cost % is not ranked ^*
in the Diversified Financial Services industry.
Industry Median: 4.135
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of MedTech Acquisition's 5-Year Yield-on-Cost %

For the Shell Companies subindustry, MedTech Acquisition's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedTech Acquisition's 5-Year Yield-on-Cost % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where MedTech Acquisition's 5-Year Yield-on-Cost % falls into.

MedTech Acquisition 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of MedTech Acquisition is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

MedTech Acquisition (NAS:MTACU) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

MedTech Acquisition 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of MedTech Acquisition's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

MedTech Acquisition (MedTech Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » MedTech Acquisition Corp (NAS:MTACU) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

N/A

Address

48 Maple Avenue, Greenwich, CT, USA, 06830

Website

MedTech Acquisition Corp is a blank check company.

Executives

Magnetar Financial Llc	10 percent owner	1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Magnetar Capital Partners Lp	10 percent owner	1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Supernova Management Llc	10 percent owner	1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David J. Snyderman	10 percent owner	C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David L Treadwell	director	222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102
Manuel Aguero	director	600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Thierry B. Thaure	director	3957 POINT EDEN WAY, HAYWARD CA 94545
David J Matlin	director, 10 percent owner, officer: Chief Financial Officer
Karim Karti	director	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Christopher C Dewey	director, 10 percent owner, officer: Chief Executive Officer	120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Robert H. Weiss	officer: Chief Admin Officer and Sec.	585 WEED STREET, NEW CANAAN CT 06840
Maurice R Ferre	director	C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317
Ivan Delevic	director	C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317
Medtech Acquisition Sponsor Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Martin William Roche	director	600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022